Add like
Add dislike
Add to saved papers

Orforglipron may be a safe and effective oral GLP-1 agonist for treatment of type 2 diabetes

2 Minute Medicine 2023 August 17

1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups.

2. The majority of treatment-related adverse events were mild-to-moderate in nature.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Glucagon-like peptide (GLP-1) receptor agonists are emerging as first-line therapies for the management of type 2 diabetes (T2D). Currently, semaglutide is the only orally administered GLP-1 agonist available. Orforglipron is a novel non-peptide GLP-1 agonist that may be superior to current therapy for T2D with pharmacokinetics that supports once-per-day dosing. This randomized controlled trial aimed to assess the safety and efficacy of orforglipron versus dulaglutide and placebo. The primary outcome of this study was mean change in glycated hemoglobin (HbA1c) from baseline to 26 weeks, while key secondary outcome included mean change in body weight. According to study results, oral orforglipron showed significant superiority versus placebo for mean reduction in HbA1c and body weight at 26 weeks. Although this study was well done, it was limited by a short follow-up, thus affecting the validity of the findings.

Click to read the study in The Lancet

Relevant Reading: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

In-depth [randomized-controlled trial]: Between Sept 15, 2021, and Sept 30, 2022, 569 patients were screened for eligibility across 45 centers in the USA, Hungary, Poland, and Slovakia. Included were patients ≥ 18 years with T2D, treated with or without metformin, with HbA1c 7.0-10.5% and BMI ≥ 23 kg/m2. Altogether, 383 patients (enrolled in placebo, dulaglutide 1.5 mg, and orforglipron 3 mg, 12 mg, 24 mg, 36 mg, and 45 mg) were included in the final analysis. The mean patient age was 58.9 years, mean HbA1c was 8.1%, mean BMI was 35.2 kg/m2, and the majority (59%) were men. The primary outcome of reduction in HbA1c at 26 weeks was -2.10% with orforglipron, -1.10% with dulaglutide, and -0.43% with placebo. Similarly, the secondary outcome of mean change in body weight was -10.1 kg with orforglipron (95% confidence interval [CI] -11.5 to -8.7), -3.9 kg with dulaglutide (95% CI -5.3 to -2.4), and -2.2 kg with placebo (95% CI -3.6 to -0.7). Overall, findings from this study suggest that orforglipron holds promise as an effective and convenient alternative for managing type 2 diabetes and obesity.

Originally Published By 2 Minute Medicine®. Reused on Read by QxMD with permission.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Add to Saved Papers

Get 1-tap access

Urinary Tract Infections: Core Curriculum 2024.American Journal of Kidney Diseases 2023 October 31

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app